Leonard H. Evans, Ph.D.
Retroviral Molecular Biology Section
Rocky Mountain Laboratories
Building 3, Room 3118
903 South 4th Street
Hamilton, MT 59840
A major focus of our laboratory is the effect of mixed retrovirus infections on viral replication and pathology in the host. Mixed infections can result from infection with a heterogeneous population of viruses or by genetic alterations of retroviruses, such as point mutations or recombination that may occur subsequent to infection.
Much of our research has concerned the interactions of inoculated retroviruses (exogenous retroviruses) with their endogenous counterparts in mice in an effort to elucidate some of the general principals of in vivo retroviral interactions. Upon infection, exogenous mouse retroviruses undergo recombination with endogenous retroviruses to generate variants with different infectious properties. Our studies involve the characterization of the endogenous viruses, the mechanism of recombination of the endogenous viruses with exogenous viruses, and the effect of the resulting mixed infection on pathogenesis.
In another approach to mixed retrovirus infections, we have studied the co-inoculation of mixtures of retroviruses. In recent studies, we have found that inoculation of two nonpathogenic retroviruses as a mixture induces a neurological disease in mice which ranks as one of the most rapidly progressive retroviral diseases ever observed.
Considering that all mammals harbor a very large number of retroviruses in their genomes, infection of mammals by any exogenous retrovirus may be considered to result in a mixed retrovirus infection. Approximately 8 percent of the genomes of mammals, including humans and mice, are composed of retroviral elements acquired by infection of germ line cells during the course of evolution. Retroviral insertions in our genome number about 40,000 and are in the same range as the total number of genes encoded by our DNA. The impact of endogenous retrovirus insertions on evolution and the extent to which functional retroviral elements have been utilized in our own physiological processes is an emerging area of study.
In this regard, although most of the endogenous retroviruses are defective and, for the most part, quiescent, some appear to be intact. Several contain one or more intact viral genes that are expressed during development and certain physiological or pathological conditions. The expression of endogenous retroviruses and their control is not well understood. Our recent characterization of endogenous retroviruses in mice has enabled us to initiate studies examining the detailed expression of the endogenous retroviruses during development. In addition, we are examining the effects of exogenous retrovirus infection on the expression and mobilization of endogenous retroviruses.
Dr. Evans received his Ph.D. in biochemistry in 1977 at the Oregon Health Sciences University in Portland. He did postdoctoral studies on the genetic structure of retroviruses in the Department of Molecular and Cellular Biology at the University of California at Berkeley from 1977 until 1980. In 1980, he joined the Rocky Mountain Laboratories, where he is currently a senior investigator in the Laboratory of Persistent Viral Diseases.
Rosenke K, Lavignon M, Malik F, Kolokithas A, Hendrick D, Virtaneva K, Peterson K, Evans LH. Profound amplification of pathogenic murine polytropic retrovirus release from coinfected cells. J Virol. 2012;86(13):7241-8.
Boi S, Kolokithas A, Shepard J, Linwood R, Rosenke K, Van Dis E, Malik F, Evans LH. Incorporation of mouse APOBEC3 into murine leukemia virus virions decreases the activity and fidelity of reverse transcriptase. J Virol. 2014;88(13):7659-62.
Smith DS, Guo K, Barrett BS, Heilman KJ, Evans LH, Hasenkrug KJ, Greene WC, Santiago ML. Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog. 2011;7(10):e1002284.
Evans LH, Boi S, Malik F, Wehrly K, Peterson KE, Chesebro B. Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus. J Virol Methods. 2014;200:47-53.
Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, Portis JL, Hasenkrug KJ, Evans LH. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol. 2010;84(20):10933-6.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on April 24th, 2018